New PET tracer could reveal hidden cancer response in breast cancer patients

NCT ID NCT06502691

Recruiting now Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times

Summary

This study is testing a special radioactive tracer called [18F]FTT that attaches to a protein (PARP1) found in some cancer cells. By using a PET scan, doctors hope to see if the tracer can show how well standard treatments (PARP inhibitors with or without immunotherapy) are working in people with metastatic breast cancer. The study will enroll 22 adults whose cancer has spread and who are already eligible for these treatments. The goal is to improve imaging of tumor response, not to test a new therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ANATOMIC STAGE IV BREAST CANCER AJCC V8 METASTATIC BREAST CARCINOMA